The securities described above are being offered by Fate Therapeutics pursuant to an automatic shelf registration statement on Form S-3 (File No. NEW YORK, March 4, 2023 /PRNewswire/ --. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. The stock price of Fate Therapeutics (NASDAQ: FATE), a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a large 20%. A change of 16% or more over 5 trading days is a 9% likelihood event, which has occurred 114 times out of 1256 in the last 5 years, A change of 13% or more over 10 trading days is a 20% likelihood event, which has occurred 252 times out of 1240 in the last 5 years. Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The stock has a market capitalization of $599.76 million, a price-to-earnings ratio of -2.10 and a beta of 1.53.. FT819 comprises precise genetic engineering of multiple targeting events at the single cell level and is produced using a clonally-derived master cell bank (MCB) that serves as the starting material to support consistent and reproducible clinical manufacturing. 1 dividend stock for a LIFETIME of income. Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Today it has 9 INDs, more than 250. Shares climbed about 20%, to around $25 apiece, in pre-market trading Friday. The collaboration strengthens our financial and operating position through a focused effort of developing cell-based cancer immunotherapies utilizing Janssens proprietary antigen-binding domains while enabling us to continue to exploit our deep pipeline of wholly-owned product candidates and further develop our off-the-shelf, iPSC-derived cell-based immunotherapies, Wolchko said in a statement. What happened When Celgene announced it was acquiring Juno. Fate Therapeutics, Inc. (NASDAQ: FATE) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Welcome to the Fate Therapeutics Fourth Quarter 2022 Financial Results Conference Call.. Boothbay Fund Management LLC Purchases Shares of 4,711 Graco Inc. UBS Group AG Reduces Stock Holdings in Builders FirstSource, Inc. (NYSE:BLDR), Boothbay Fund Management LLC Has $299,000 Stock Holdings in GMS Inc. (NYSE:GMS), Alphabet Inc. (NASDAQ:GOOG) Shares Bought by Capital Square LLC, Jeereddi Investments LP Increases Position in Alphabet Inc. (NASDAQ:GOOG), Boothbay Fund Management LLC Buys Shares of 4,680 Sonoco Products (NYSE:SON), Boothbay Fund Management LLC Purchases Shares of 4,711 Graco Inc. (NYSE:GGG), MML Investors Services LLC Buys 3,360 Shares of Wolfspeed, Inc. (NYSE:WOLF), Boothbay Fund Management LLC Takes Position in Loews Co. (NYSE:L), Boothbay Fund Management LLC Sells 9,611 Shares of Portillos Inc. (NASDAQ:PTLO), MML Investors Services LLC Sells 139 Shares of Extra Space Storage Inc. (NYSE:EXR), Lazard Asset Management LLC Has $308,000 Stake in Marqeta, Inc. (NASDAQ:MQ), Lazard Asset Management LLC Has $329,000 Position in The Williams Companies, Inc. (NYSE:WMB), Boothbay Fund Management LLC Invests $267,000 in Synaptics Incorporated (NASDAQ:SYNA), 7,728 Shares in SEI Investments (NASDAQ:SEIC) Acquired by Ergoteles LLC, Lazard Asset Management LLC Trims Stake in iQIYI, Inc. (NASDAQ:IQ), 2,549 Shares in Hess Co. (NYSE:HES) Acquired by Boothbay Fund Management LLC, The Interpublic Group of Companies, Inc. (NYSE:IPG) Shares Sold by Lazard Asset Management LLC, Boothbay Fund Management LLC Acquires 38,651 Shares of Consolidated Communications Holdings, Inc. (NASDAQ:CNSL), Boothbay Fund Management LLC Takes $260,000 Position in Advanced Drainage Systems, Inc. (NYSE:WMS), Boothbay Fund Management LLC Takes $288,000 Position in ShotSpotter, Inc. (NASDAQ:SSTI). Gilead to Acquire Forty Seven for $4.9 Billion - Gilead Gains Forty Seven's Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma - Fate Therapeutics (NASDAQ:FATE) Price Target Lowered to $7.00 at Piper Sandler, Fate Therapeutics (NASDAQ:FATE) Receives "Buy" Rating from EF Hutton Acquisition Co. [Updated: 3/31/2021] Can FATE Stock Rebound? Fates revenue did grow a solid 160% from $4.1 million in 2017 to $10.7 million in 2019. Topics covered: Gene replacement therapy, gene editing, engineered cell therapy, manufacturing, pricing, reimbursement and much more. Raymond James & Associates now owns 29,436 shares of the biopharmaceutical companys stock worth $1,141,000 after purchasing an additional 8,790 shares during the period. Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide Bemarituzumab is a Strong Strategic Fit With Amgen's Innovative Oncology Portfolio Amgen to Host Investor Call at 10:30 a.m. EST Following the sale, the chief executive officer now owns 385,639 shares of the companys stock, valued at approximately $2,020,748.36. This company's $6.7 billion market cap at the moment assumes a great deal of success down the road. It is engaged in the development of programmed cellular immunotherapies for cancer and immune. Shares of FATE stock opened at $6.01 on Tuesday. Get daily stock ideas from top-performing Wall Street analysts. Finally, Great West Life Assurance Co. Can bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $91,000. Fate Therapeutics (NASDAQ:FATE Get Rating) was upgraded by equities researchers at StockNews.com from a sell rating to a hold rating in a research note issued on Thursday. Fate Therapeutics employees are showing high interest in Vehicle Inventory Acquisition , Attack Surface , and Eclipse IDE, according to Bombora. Overall, 124 CPI-experienced (NPCB, n = 35; PCB, n = 89) and 32 CPI-nave patients were treated. The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. The biotech Nektar Therapeutics said late Monday that it would cut 70% of its workforce in an effort to extend its cash runway after the failure of its cancer drug partnership with Bristol Myers. View our FATE earnings forecast. The coronavirus pandemic, however, has threatened clinical research timelines across the industry, disrupting study enrollment and treatment. However, the company saw a 62% growth in total shares outstanding due to share issuances, resulting in only a 61% growth in revenue per share to $0.16 in 2019, compared to $0.10 in 2017. The shares were bought at an average price of $5.67 per share, with a total value of $499,232.16. View analysts price targets for FATE or view top-rated stocks among Wall Street analysts. Is UnitedHealth Stock A Better Pick Over This Healthcare Facility Company? A high percentage of insider ownership can be a sign of company health. While the usual process is to create a different batch for each patient from their own stem cells, Fate is intending for mass production of such treatment. We believe the stock has rallied meaningfully and it is likely to see downside after the recent uptick. You can test the chance of recovery over different time intervals of a quarter, month, or even just one day! Shares of Fate Therapeutics were up more than 21% in premarket trading after the company announced a multi-billion dollar deal with Janssen Biotech to develop cell therapies for the treatment of cancer. Most of the 18x rise of the last 3 years can be attributed to expansion of its P/S multiple, as the company does not have any marketable product yet. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. However, looking at the P/S for Fate is not helpful given the company doesnt have any marketable product yet, and it is more of a story of exciting products in the pipeline. Fate Therapeutics, Inc. (NASDAQ:FATE) issued its quarterly earnings results on Tuesday, February, 28th. HighTower Advisors LLC boosted its holdings in shares of Fate Therapeutics by 5.9% in the 1st quarter. Fate Therapeutics saw its shares in the red after-hours Thursday night as durability concerns cast a shadow over its latest blood cancer data drop. To The Moon: Intuitive Machines Blasts 10x in a WeekBut Why? And it couldnt be more wrong! View which stocks are hot on social media with MarketBeat's trending stocks report. Finally, PNC Financial Services Group Inc. increased its holdings in shares of Fate Therapeutics by 17.1% during the 1st quarter. publish chart | save to portfolio | create alert | compare perf. Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE.". 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. During the same quarter in the prior year, the firm posted ($0.72) EPS. The firm has a fifty day moving average of $7.23 and a 200-day moving average of $17.23. WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023, both dates inclusive (the "Class Period"). The P/E ratio of Fate Therapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. 17.34% of the stock is owned by insiders. In other Fate Therapeutics news, CEO J Scott Wolchko sold 45,907 shares of the firms stock in a transaction on Tuesday, January 10th. [Updated: 2/10/2021] Can The FATE Stock Rally Continue? Here's what Wall Street expects from Fate Therapeutics's earnings report, Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates, Fate Therapeutics GAAP EPS of -$0.58 beats by $0.29, revenue of $44.34M beats by $25.93M, FATE's Q4 Loss Narrower Than Expected, Pipeline in Focus, Brokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) Price Target at $26.14, NK Cell Therapy Market 2023 to 2026 CONSUMER INSIGHTS with Dynamics Scenario, Induced Pluripotent Stem Cells (iPSCs) Market Size, Share & Trends Analysis Forecast Report by 2028, Fate Therapeutics (NASDAQ:FATE) Stock Price Down 7%, Natural Killer Cell Therapy Market Size 2023 NEWEST INDUSTRY DATA with Recent Industry Developments till 2028, Natural Killer Cell Therapy Market (New Insights Report) By 2023 which is Booming Strong Growth in the Globe till 2028, FATE Investors Have Opportunity to Lead Fate Therapeutics, Inc. Securities Fraud Lawsuit, Fate Therapeutics, Inc. (FATE) Class Action: Contact Robbins LLP for Information Regarding the Class Action and Lead Plaintiff Deadline, Outset Medical, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session, Needham Reaffirms Their Buy Rating on G1 Therapeutics (GTHX), Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results, ALERT: Investors in Fate Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FATE, CLASS ACTION UPDATE for AVYA, FATE and PHI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders, CLASS ACTION UPDATE for ENVX, YMAB and FATE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders, view top-rated stocks among Wall Street analysts, 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. [] According to the Trefis Machine Learning Engine, which identifies trends in a companys stock price using historical stock data, returns for FATE stock average around 6% in the next one-month (twenty-one trading days) period after experiencing a 5% fall in a week (five trading days). What is Fate Therapeutics' stock price forecast for 2023? Transforming the lives of patients with cancer and immune disorders. Do Wall Street analysts like Fate Therapeutics more than its competitors? Candle - advanced Intraday Daily Weekly Draw Fullscreen Settings FATE - Stock Price Chart FATE [NASD] Fate Therapeutics, Inc. Under terms of the agreement, Fate will receive $50 million in upfront cash, as well as a $50 million equity investment by Janssen. Former Qualcomm CEO Steven Mollenkopf, who retired in June 2021, pulled in total compensation of $69 million last year, which ranked highest among CEOs of the region's 100 publicly traded companies. Fate Therapeutics Market Cap Make that two consecutive days of riding the momentum from the Juno Therapeutics acquisition. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Their FATE share price forecasts range from $7.00 to $90.00. Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Lazard Asset Management LLC Benzinga 4 days ago FATE SHAREHOLDER NOTICE: Hagens Berman, National Trial Attorneys, Encourages Fate. Export data to Excel for your own analysis. Per deal terms, J&J will buy $50 million Fate shares at $31 apiece, a roughly 47% premium to Fate's $21.07 closing price on Thursday. Press Releases. For example, youll be surprised how counter-intuitive the stock valuation is for Pfizer vs Merck. 22 Wall Street research analysts have issued twelve-month price objectives for Fate Therapeutics' stock.